Possibilities of Adaptation Processes Disorders Correction in Patients with Uterine Cancer in the Perioperative Period

Background. It is well known that patients with uterine cancer (UC) experience disturbances in adaptation processes during the surgical stage of treatment, which are especially pronounced in the perioperative period. These phenomena have almost never been studied, but they exist and require the use of therapeutic agents capable of influencing the systemic adaptive-regulatory control mechanisms involved in the pathological process. Such agents include the metabolic drug Remaxol®, one of the possible mechanisms of which is the formation of adaptive homeostasis by increasing the pool of general non-specific adaptive reactions (GNAR) of the physiological type. The aim of the study was to determine the effect of Remaxol® on the possibility of forming adaptive reactions and correcting adaptive homeostasis in patients with UC in the perioperative period. Material and methods. The prospective study included 72 patients with verified UC, aged 56–72 years. All patients were comparable by age, extent of the process, anthropometry, and were randomly distributed into the main(N = 39) and control groups (N = 33). In the main group, Remaxol® (inosine + meglumine + methionine + nicotinamide + succinic acid) was included in therapeutic support in order to compensate for regulatory-adaptive mechanisms. It was administered intraoperatively and during the first 4 days of the perioperative period. Remaxol® was not prescribed in the control group. The structure and type of GNAR characterizing the adaptation status, its systemic interrelations, the level of reactivity in quantitative terms, were identified based on the morphological composition of the blood. Results. The main types of general adaptive reactions and their structure in UC patients were determined. An analysis of GNAR development was carried out when Remaxol® was included in the perioperative treatment program. It was shown that its use in the system of therapeutic measures reduces the impact of surgical stress in the perioperative period. Conclusion. The use of Remaxol® promotes the sustainable development of a sufficient number of anti-stress reactions of physiological orientation, as well as high resistance with subsequent stabilization of adaptive homeostasis in UC patients in the perioperative period.